STRM.BIO, a pre-clinical, VC-backed biotechnology company based in Boston, MA, has successfully raised $8.0 million in new investment capital. This funding round will support the company's mission to advance gene therapy by leveraging extracellular vesicles (EVs) for direct, in vivo treatment delivery. The secured capital represents a significant milestone for STRM.BIO as it progresses its innovative platform.
STRM.BIO's core technology centers on utilizing extracellular vesicles, which are natural carriers of nucleic acids and proteins. These EVs offer distinct advantages over traditional viral vectors, including innate targeting capabilities, amenability to large-scale commercial manufacture, and low immunogenicity. The company's proprietary EV platform is designed to establish a novel class of therapeutics, with the potential to yield new treatments and enhance the efficacy of existing ones.
The $8.0 million in secured funds will be strategically deployed to accelerate STRM.BIO's pre-clinical programs and further develop its extracellular vesicle platform. This investment is crucial for expanding research and development initiatives aimed at translating its scientific breakthroughs into tangible therapeutic solutions. The capital infusion reflects investor confidence in STRM.BIO's innovative approach to overcoming current limitations in gene therapy delivery.
Looking ahead, STRM.BIO is committed to its vision of democratizing gene therapy, aiming to bring hope to patients fighting rare diseases globally. By developing a new generation of therapeutics, the company believes its work can make gene therapies more accessible and effective for a broader patient population. This funding round positions STRM.BIO to continue its critical work towards making its life-saving vision a reality.
